{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:11:57Z","timestamp":1783779117836,"version":"3.55.0"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objectives were to evaluate etripamil, an intranasal L-type nondihydropyridine calcium channel blocker (CCB), for the treatment of acute supraventricular tachycardia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>We conducted a literature search from PubMed, Embase, Cochrane, and Web of Science using key words etripamil, CARDAMYST, and MSP-2017 until April 2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>We analyzed English-language studies focusing on the pharmacology, efficacy, and safety of etripamil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Etripamil is a fast-acting intranasal CCB developed for the acute management of paroxysmal supraventricular tachycardia (PSVT). Etripamil significantly increased the rate and shortened the time to conversion of acute symptomatic, atrioventricular node-dependent PSVT to sinus rhythm compared with placebo. Etripamil was generally well tolerated; adverse events were primarily mild to moderate and intranasal-related. Notably, there was no significant increase in serious adverse events compared with placebo, with cardiovascular events being rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Etripamil nasal spray is the first nonparenteral, patient-administered therapy approved for the acute termination of PSVT. Etripamil is the only intranasal agent that significantly increases conversion to sinus rhythm compared with placebo in phase III trials. However, its role in certain higher-risk populations, including patients with atrial fibrillation with rapid ventricular rates, remains to be further defined in post-marketing studies and clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Etripamil is an effective and well-tolerated intranasal medication for the acute treatment of PSVT in adults, providing rapid conversion to sinus rhythm and offering a safe, patient-administered option to reduce symptom burden and potentially decrease emergency department utilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280261454696","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:38:23Z","timestamp":1783571903000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Etripamil: The First FDA-Approved Intranasal L-Type Calcium Channel Blocker for Acute Termination of Paroxysmal Supraventricular Tachycardia"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2709-285X","authenticated-orcid":false,"given":"Azadeh","family":"Nasuhidehnavi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-1899","authenticated-orcid":false,"given":"Rachel C","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8444-0862","authenticated-orcid":false,"given":"Kelly","family":"Bach","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-6582","authenticated-orcid":false,"given":"Anthony B.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000311"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0076"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acepjo.2026.100343"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.71.1.104"},{"key":"e_1_3_3_6_2","unstructured":"CARDAMYST (etripamil) [package insert]. Milestone Pharmaceuticals USA Inc. Published December 2025. Accessed March 12 2026. https:\/\/milestonepharma.com\/etripamilprescribinginformation.pdf"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1144069"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1383"},{"key":"e_1_3_3_9_2","unstructured":"Ip J Noseworthy P Rafii F et al. Minimal blood pressure effects of intranasal etripamil for PSVT. Poster presented at the ACC.26; March 29 2026; New Orleans LA. Accessed April 20 2026. https:\/\/milestonepharma.com\/wp-content\/uploads\/2026\/03\/Poster_2026_ACC_Blood-Pressure-Hypotension-and-Syncope_Website.pdf"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.082"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198938010-00003"},{"key":"e_1_3_3_12_2","unstructured":"Etripamil. Lexi-drugs. UpToDate Lexidrug. UpToDate Inc. Accessed March 7 2026. https:\/\/online.lexi.com\/"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.122.010915"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00776-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.028227"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jce.70086"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz467"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(00)01128-1"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S101700"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.15159"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2025.0417"},{"key":"e_1_3_3_22_2","unstructured":"CARDAMYST (etripamil) nasal spray. Accessed May 25 2026. https:\/\/www.cardamyst.com\/"},{"key":"e_1_3_3_23_2","unstructured":"Active Ingredient: CARDAMYST. RED BOOK Online. Micromedex [database online]; 2026. Accessed May 7 2026. https:\/\/www.micromedexsolutions.com\/home\/dispatch"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193"},{"key":"e_1_3_3_25_2","unstructured":"Milestone Pharmaceuticals Inc. ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (ReVeRA-301). ClinicalTrials.gov; 2026. Accessed March 7 2026. https:\/\/clinicaltrials.gov\/study\/NCT06716021"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.09.001"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/circep.123.012567"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jce.70287"},{"key":"e_1_3_3_30_2","unstructured":"Fermann G Piccini J Steinberg B et al. Registry of etripamil (CARDAMYSTTM) studies evaluating treatment in paroxysmal supraventricular tachycardia (RESET-PSVT): study design. Poster presented at the Cardiovascular Nursing Symposium 2026; April 9-11 2026; Scottsdale AZ. Accessed April 20 2026. https:\/\/milestonepharma.com\/wp-content\/uploads\/2026\/04\/PCNA_2026_Registry-Design_032426.pdf"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261454696","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280261454696","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280261454696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:21:32Z","timestamp":1783776092000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280261454696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":29,"alternative-id":["10.1177\/10600280261454696"],"URL":"https:\/\/doi.org\/10.1177\/10600280261454696","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"10600280261454696"}}